AMP-Activated Protein Kinase 1 Regulates Cardiac Gap Junction Protein Connexin 43 and Electrical Remodeling Following Pressure Overload

Cellular Physiology and Biochemistry

Volumn 35, Issue 1, 2015, Pages 406-418

  Alesutan, Ioana ^a   Voelkl, Jakob ^a   Stöckigt, Florian ^b   Mia, Sobuj ^a   Feger, Martina ^a   Primessnig, Uwe ^c   Sopjani, Mentor ^a,e   Munoz, Carlos ^a   Borst, Oliver ^a   Gawaz, Meinrad ^a   Pieske, Burkert ^c   Metzler, Bernhard ^d   Heinzel, Frank ^c   Schrickel, Jan Wilko ^b   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF PRISHTINA   (Serbia)

Author keywords

Ampk1; Conduction; Cx43; Electrical remodeling; Ubiquitination

Indexed keywords

ADENOSINE 5' MONOPHOSPHATE ACTIVATED PROTEIN KINASE ALPHA 1; CONNEXIN 43; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; UNCLASSIFIED DRUG; AMPK ALPHA1 SUBUNIT, MOUSE;

ANIMAL TISSUE; AORTA CONSTRICTION; ARRHYTHMOGENESIS; ARTICLE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GAP JUNCTION; GENOTYPE; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE CONDUCTION; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; IN VIVO STUDY; MALE; MOUSE; NERVE BLOCK; NONHUMAN; OOCYTE; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING; XENOPUS; AMINO ACID SUBSTITUTION; ANIMAL; CONFOCAL MICROSCOPY; DEFICIENCY; ELECTROPHYSIOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEART ATRIUM REMODELING; HEART MUSCLE; KNOCKOUT MOUSE; METABOLISM; PRESSURE;

MUS;

AMINO ACID SUBSTITUTION; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ATRIAL REMODELING; CONNEXIN 43; DOWN-REGULATION; ELECTROPHYSIOLOGICAL PHENOMENA; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MYOCARDIUM; OOCYTES; PRESSURE; RNA, MESSENGER; UBIQUITINATION; XENOPUS;

EID: 84921387454     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369706     Document Type: Article

References (66)

1. Fontes MS, Van Veen TA, de Bakker JM, Van Rijen HV: Functional consequences of abnormal Cx43 expression in the heart. Biochim Biophys Acta 2012;1818:2020-2029.
2. Hesketh GG, Van Eyk JE, Tomaselli GF: Mechanisms of gap junction traffic in health and disease. J Cardiovasc Pharmacol 2009;54:263-272.
3. Cutler MJ, Jeyaraj D, Rosenbaum DS: Cardiac electrical remodeling in health and disease. Trends Pharmacol Sci 2011;32:174-180.
4. Ghali JK, Kadakia S, Cooper RS, Liao YL: Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991;17:1277-1282.
5. Zaha VG, Young LH: AMP-Activated protein kinase regulation and biological actions in the heart. Circ Res 2012;111:800-814.
6. Towler MC, Hardie DG: AMP-Activated protein kinase in metabolic control and insulin signaling. Circ Res 2007;100:328-341.
7. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, Andreelli F: AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 2010;45:276-295.
8. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ: Increased adenosine monophosphate-Activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001;104:1664-1669.
9. Kim M, Shen M, Ngoy S, Karamanlidis G, Liao R, Tian R: AMPK isoform expression in the normal and failing hearts. J Mol Cell Cardiol 2012;52:1066-1073.
10. Alesutan I, Munoz C, Sopjani M, Dermaku-Sopjani M, Michael D, Fraser S, Kemp BE, Seebohm G, Foller M, Lang F: Inhibition of Kir2.1 (KCNJ2) by the AMP-Activated protein kinase. Biochem Biophys Res Commun 2011;408:505-510.
11. Light PE, Wallace CH, Dyck JR: Constitutively active adenosine monophosphate-Activated protein kinase regulates voltage-gated sodium channels in ventricular myocytes. Circulation 2003;107:1962-1965.
12. Alesutan I, Sopjani M, Munoz C, Fraser S, Kemp BE, Foller M, Lang F: Inhibition of connexin 26 by the AMP-Activated protein kinase. J Membr Biol 2011;240:151-158.
13. Gusarova GA, Dada LA, Kelly AM, Brodie C, Witters LA, Chandel NS, Sznajder JI: Alpha1-AMP-Activated protein kinase regulates hypoxia-induced Na,K-ATPase endocytosis via direct phosphorylation of protein kinase C zeta. Mol Cell Biol 2009;29:3455-3464.
14. Vadasz I, Dada LA, Briva A, Trejo HE, Welch LC, Chen J, Toth PT, Lecuona E, Witters LA, Schumacker PT, Chandel NS, Seeger W, Sznajder JI: AMP-Activated protein kinase regulates CO2-induced alveolar epithelial dysfunction in rats and human cells by promoting Na,K-ATPase endocytosis. J Clin Invest 2008;118:752-762.
15. Bhavsar SK, Schmidt S, Bobbala D, Nurbaeva MK, Hosseinzadeh Z, Merches K, Fajol A, Wilmes J, Lang F: AMPKalpha1-sensitivity of Orai1 and Ca(2+) entry in T-lymphocytes. Cell Physiol Biochem 2013;32:687-698.
16. Langelueddecke C, Jakab M, Ketterl N, Lehner L, Hufnagl C, Schmidt S, Geibel JP, Fuerst J, Ritter M: Effect of the AMP-kinase modulators AICAR, metformin and compound C on insulin secretion of INS-1E rat insulinoma cells under standard cell culture conditions. Cell Physiol Biochem 2012;29:75-86.
17. Mia S, Munoz C, Pakladok T, Siraskar G, Voelkl J, Alesutan I, Lang F: Downregulation of Kv1.5 K channels by the AMP-Activated protein kinase. Cell Physiol Biochem 2012;30:1039-1050.
18. Zhu Y, Wu J, Yuan SY: MCT1 and MCT4 expression during myocardial ischemic-reperfusion injury in the isolated rat heart. Cell Physiol Biochem 2013;32:663-674.
19. Alesutan I, Foller M, Sopjani M, Dermaku-Sopjani M, Zelenak C, Frohlich H, Velic A, Fraser S, Kemp BE, Seebohm G, Volkl H, Lang F: Inhibition of the heterotetrameric K+ channel KCNQ1/KCNE1 by the AMP-Activated protein kinase. Mol Membr Biol 2011;28:79-89.
20. Kim M, Hunter RW, Garcia-Menendez L, Gong G, Yang YY, Kolwicz SC, Jr., Xu J, Sakamoto K, Wang W, Tian R: Mutation in the gamma2-subunit of AMP-Activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res 2014;114:966-975.
21. Jorgensen SB, Viollet B, Andreelli F, Frosig C, Birk JB, Schjerling P, Vaulont S, Richter EA, Wojtaszewski JF: Knockout of the alpha2 but not alpha1 5'-AMP-Activated protein kinase isoform abolishes 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 2004;279:1070-1079.
22. Schuhmacher S, Foretz M, Knorr M, Jansen T, Hortmann M, Wenzel P, Oelze M, Kleschyov AL, Daiber A, Keaney JF, Jr., Wegener G, Lackner K, Munzel T, Viollet B, Schulz E: alpha1AMP-Activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation. Arterioscler Thromb Vasc Biol 2011;31:560-566.
23. Voelkl J, Lin Y, Alesutan I, Ahmed MS, Pasham V, Mia S, Gu S, Feger M, Saxena A, Metzler B, Kuhl D, Pichler BJ, Lang F: Sgk1 sensitivity of Na(+)/H(+) exchanger activity and cardiac remodeling following pressure overload. Basic Res Cardiol 2012;107:236.
24. Kreuzberg MM, Schrickel JW, Ghanem A, Kim JS, Degen J, Janssen-Bienhold U, Lewalter T, Tiemann K, Willecke K: Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node. Proc Natl Acad Sci U S A 2006;103:5959-5964.
25. Schrickel JW, Brixius K, Herr C, Clemen CS, Sasse P, Reetz K, Grohe C, Meyer R, Tiemann K, Schroder R, Bloch W, Nickenig G, Fleischmann BK, Noegel AA, Schwinger RH, Lewalter T: Enhanced heterogeneity of myocardial conduction and severe cardiac electrical instability in annexin A7-deficient mice. Cardiovasc Res 2007;76:257-268.
26. Schrickel JW, Stockigt F, Krzyzak W, Paulin D, Li Z, Lubkemeier I, Fleischmann B, Sasse P, Linhart M, Lewalter T, Nickenig G, Lickfett L, Schroder R, Clemen CS: Cardiac conduction disturbances and differential effects on atrial and ventricular electrophysiological properties in desmin deficient mice. J Interv Card Electrophysiol 2010;28:71-80.
27. Lammers WJ, Schalij MJ, Kirchhof CJ, Allessie MA: Quantification of spatial inhomogeneity in conduction and initiation of reentrant atrial arrhythmias. Am J Physiol 1990;259:H1254-1263.
28. Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro OM, Lang F: Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 2013;123:812-822.
29. Fraser SA, Gimenez I, Cook N, Jennings I, Katerelos M, Katsis F, Levidiotis V, Kemp BE, Power DA: Regulation of the renal-specific Na+-K+-2Cl-co-transporter NKCC2 by AMP-Activated protein kinase (AMPK). Biochem J 2007;405:85-93.
30. Hamilton SR, Stapleton D, O'Donnell JB, Jr., Kung JT, Dalal SR, Kemp BE, Witters LA: An activating mutation in the gamma1 subunit of the AMP-Activated protein kinase. FEBS Lett 2001;500:163-168.
31. Hallows KR, Kobinger GP, Wilson JM, Witters LA, Foskett JK: Physiological modulation of CFTR activity by AMP-Activated protein kinase in polarized T84 cells. Am J Physiol Cell Physiol 2003;284:C1297-C1308.
32. Warsi J, Dong L, Elvira B, Salker MS, Shumilina E, Hosseinzadeh Z, Lang F: SPAK Dependent Regulation of Peptide Transporters PEPT1 and PEPT2. Kidney Blood Press Res 2014;39:388-398.
33. Elvira B, Munoz C, Borras J, Chen H, Warsi J, Ajay SS, Shumilina E, Lang F: SPAK and OSR1 Dependent Down-Regulation of Murine Renal Outer Medullary K Channel ROMK1. Kidney Blood Press Res 2014;39:353-360.
34. Munoz C, Pakladok T, Almilaji A, Elvira B, Decher N, Shumilina E, Lang F: Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3. Cell Physiol Biochem 2014;33:491-500.
35. Drmaku-Sopjani M, Almilaji A, Pakladok T, Munoz C, Hosseinzadeh Z, Blecua M, Sopjani M, Lang F: Down-regulation of the Na+-coupled phosphate transporter NaPi-IIa by AMP-Activated protein kinase. Kidney Blood Press Res 2013;37:547-556.
36. Bukauskas FF, Kreuzberg MM, Rackauskas M, Bukauskiene A, Bennett MV, Verselis VK, Willecke K: Properties of mouse connexin 30.2 and human connexin 31.9 hemichannels: implications for atrioventricular conduction in the heart. Proc Natl Acad Sci U S A 2006;103:9726-9731.
37. O'Connor CM, Smith LD: Inhibition of oocyte maturation by theophylline: possible mechanism of action. Dev Biol 1976;52:318-322.
38. Pakladok T, Almilaji A, Munoz C, Alesutan I, Lang F: PIKfyve sensitivity of hERG channels. Cell Physiol Biochem 2013;31:785-794.
39. Ussher JR, Lopaschuk GD: Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion. Basic Res Cardiol 2009;104:203-210.
40. Boulaksil M, Winckels SK, Engelen MA, Stein M, Van Veen TA, Jansen JA, Linnenbank AC, Bierhuizen MF, Groenewegen WA, Van Oosterhout MF, Kirkels JH, de Jonge N, Varro A, Vos MA, de Bakker JM, Van Rijen HV: Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmias. Eur J Heart Fail 2010;12:913-921.
41. Laing JG, Beyer EC: The gap junction protein connexin43 is degraded via the ubiquitin proteasome pathway. J Biol Chem 1995;270:26399-26403.
42. Leithe E, Rivedal E: Ubiquitination of gap junction proteins. J Membr Biol 2007;217:43-51.
43. Leithe E, Rivedal E: Ubiquitination and down-regulation of gap junction protein connexin-43 in response to 12-O-tetradecanoylphorbol 13-Acetate treatment. J Biol Chem 2004;279:50089-50096.
44. Bhalla V, Oyster NM, Fitch AC, Wijngaarden MA, Neumann D, Schlattner U, Pearce D, Hallows KR: AMP-Activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2. J Biol Chem 2006;281:26159-26169.
45. Alzamora R, Gong F, Rondanino C, Lee JK, Smolak C, Pastor-Soler NM, Hallows KR: AMP-Activated protein kinase inhibits KCNQ1 channels through regulation of the ubiquitin ligase Nedd4-2 in renal epithelial cells. Am J Physiol Renal Physiol 2010;299:F1308-1319.
46. Baskin KK, Taegtmeyer H: AMP-Activated protein kinase regulates E3 ligases in rodent heart. Circ Res 2011;109:1153-1161.
47. Tong JF, Yan X, Zhu MJ, Du M: AMP-Activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. J Cell Biochem 2009;108:458-468.
48. Bierhuizen MF, Boulaksil M, Van Stuijvenberg L, Van der Nagel R, Jansen AT, Mutsaers NA, Yildirim C, Van Veen TA, de Windt LJ, Vos MA, Van Rijen HV: In calcineurin-induced cardiac hypertrophy expression of Nav1.5, Cx40 and Cx43 is reduced by different mechanisms. J Mol Cell Cardiol 2008;45:373-384.
49. Morley GE, Vaidya D, Samie FH, Lo C, Delmar M, Jalife J: Characterization of conduction in the ventricles of normal and heterozygous Cx43 knockout mice using optical mapping. J Cardiovasc Electrophysiol 1999;10:1361-1375.
50. Van Rijen HV, Eckardt D, Degen J, Theis M, Ott T, Willecke K, Jongsma HJ, Opthof T, de Bakker JM: Slow conduction and enhanced anisotropy increase the propensity for ventricular tachyarrhythmias in adult mice with induced deletion of connexin43. Circulation 2004;109:1048-1055.
51. Lubkemeier I, Requardt RP, Lin X, Sasse P, Andrie R, Schrickel JW, Chkourko H, Bukauskas FF, Kim JS, Frank M, Malan D, Zhang J, Wirth A, Dobrowolski R, Mohler PJ, Offermanns S, Fleischmann BK, Delmar M, Willecke K: Deletion of the last five C-terminal amino acid residues of connexin43 leads to lethal ventricular arrhythmias in mice without affecting coupling via gap junction channels. Basic Res Cardiol 2013;108:348.
52. Schrickel JW, Lickfett L, Lewalter T, Tiemann K, Nickenig G, Baba H, Heusch G, Schulz R, Levkau B: Cardiomyocyte-specific deletion of survivin causes global cardiac conduction defects. Basic Res Cardiol 2012;107:299.
53. Chkourko HS, Guerrero-Serna G, Lin X, Darwish N, Pohlmann JR, Cook KE, Martens JR, Rothenberg E, Musa H, Delmar M: Remodeling of mechanical junctions and of microtubule-Associated proteins accompany cardiac connexin43 lateralization. Heart Rhythm 2012;9:1133-1140 e1136.
54. Bruce AF, Rothery S, Dupont E, Severs NJ: Gap junction remodelling in human heart failure is associated with increased interaction of connexin43 with ZO-1. Cardiovasc Res 2008;77:757-765.
55. Teunissen BE, Jongsma HJ, Bierhuizen MF: Regulation of myocardial connexins during hypertrophic remodelling. Eur Heart J 2004;25:1979-1989.
56. Betsuyaku T, Kovacs A, Saffitz JE, Yamada KA: Cardiac structure and function in young and senescent mice heterozygous for a connexin43 null mutation. J Mol Cell Cardiol 2002;34:175-184.
57. Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E, Haussinger D: Functional significance of cell volume regulatory mechanisms. Physiol Rev. 1998;78:247-306.
58. Smyth JW, Zhang SS, Sanchez JM, Lamouille S, Vogan JM, Hesketh GG, Hong T, Tomaselli GF, Shaw RM: A 14-3-3 mode-1 binding motif initiates gap junction internalization during acute cardiac ischemia. Traffic 2014;15:684-699.
59. Li J, Coven DL, Miller EJ, Hu X, Young ME, Carling D, Sinusas AJ, Young LH: Activation of AMPK alpha-And gamma-isoform complexes in the intact ischemic rat heart. Am J Physiol Heart Circ Physiol 2006;291:H1927-1934.
60. Pei H, Qu Y, Lu X, Yu Q, Lian K, Liu P, Yan W, Liu J, Ma Y, Liu Y, Li C, Li W, Lau WB, Zhang H, Tao L: Cardiac-derived adiponectin induced by long-term insulin treatment ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic mice via AMPK signaling. Basic Res Cardiol 2013;108:322.
61. Russell RR, 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH: AMP-Activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114:495-503.
62. Wang N, De Vuyst E, Ponsaerts R, Boengler K, Palacios-Prado N, Wauman J, Lai CP, De Bock M, Decrock E, Bol M, Vinken M, Rogiers V, Tavernier J, EVans WH, Naus CC, Bukauskas FF, Sipido KR, Heusch G, Schulz R, Bultynck G, Leybaert L: Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol 2013;108:309.
63. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, Seidman JG, Seidman CE: Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357-362.
64. Luptak I, Shen M, He H, Hirshman MF, Musi N, Goodyear LJ, Yan J, Wakimoto H, Morita H, Arad M, Seidman CE, Seidman JG, Ingwall JS, Balschi JA, Tian R: Aberrant activation of AMP-Activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest 2007;117:1432-1439.
65. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, Xu W, Wiczer B, Bernlohr DA, Bache RJ, Chen Y: AMP activated protein kinase-Alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008;52:918-924.
66. Xu X, Lu Z, Fassett J, Zhang P, Hu X, Liu X, Kwak D, Li J, Zhu G, Tao Y, Hou M, Wang H, Guo H, Viollet B, McFalls EO, Bache RJ, Chen Y: Metformin Protects Against Systolic Overload-Induced Heart Failure Independent of AMP-Activated Protein Kinase alpha2. Hypertension 2014;10.1161/ HYPERTENSIONAHA.113.02619